Clinical efficacy of hyperthermic intraperitoneal chemotherapy plus cytoreductive surgery for peritoneal metastasis of gallbladder cancer
10.3969/j.issn.1000-8179.2020.03.610
- VernacularTitle: 腹腔热灌注化疗联合细胞减灭术对胆囊癌腹膜转移的临床疗效研究*
- Author:
Qingxiang GAO
1
Author Information
1. Center for Biliary Tract Oncology, Naval Military Medical University, First Department of Hepatobiliary Surgery, Shanghai Eastern Hepatobiliary Surgery Hospital
- Publication Type:Journal Article
- Keywords:
Clinical efficacy;
Gallbladder cancer;
Hyperthermic intraperitoneal chemotherapy (HIPEC);
Peritoneal metastasis;
Side effects
- From:
Chinese Journal of Clinical Oncology
2020;47(3):140-144
- CountryChina
- Language:Chinese
-
Abstract:
Objective: To investigate the clinical efficacy of hyperthermic intraperitoneal chemotherapy (HIPEC) for gallbladder cancer with peritoneal metastasis. Methods: Data of 84 patients, who were admitted to Shanghai Eastern Hepatobiliary Surgery Hospital from January 2015 to January 2018, were retrospectively analyzed. Of the total patients, 31 received HIPEC combined with cytoreductive surgery (CRS) plus postoperative systemic chemotherapy one month after surgery as the study group (Group A), and the other 53 underwent CRS plus postoperative systemic chemotherapy one momth after surgery as the control group (Group B). The clinical effects and adverse reactions in the two groups were observed and compared. Results: The median survival time in the Group A was (21.72±2.96) months, significantly longer than that of (14.93±2.09) months in Group B (P<0.05). There were no statistically significant differences in leukopenia, hemoglobinemia, thrombocytopenia, gastrointestinal reaction, liver function injury and renal function injury-between the two groups (P>0.05). Conclusions: HIPEC has significant clinical efficacy for gallbladder cancer with peritoneal metastasis. HIPEC can prolong the survival time and have less side effects.
